BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31964784)

  • 1. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
    Quayle SN; Girgis N; Thapa DR; Merazga Z; Kemp MM; Histed A; Zhao F; Moreta M; Ruthardt P; Hulot S; Nelson A; Kraemer LD; Beal DR; Witt L; Ryabin J; Soriano J; Haydock M; Spaulding E; Ross JF; Kiener PA; Almo S; Chaparro R; Seidel R; Suri A; Cemerski S; Pienta KJ; Simcox ME
    Clin Cancer Res; 2020 Apr; 26(8):1953-1964. PubMed ID: 31964784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
    mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice.
    Ding Z; Ou R; Ni B; Tang J; Xu Y
    Clin Vaccine Immunol; 2013 Jul; 20(7):1027-33. PubMed ID: 23658393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
    Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
    J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.
    Hoffmann TK; Arsov C; Schirlau K; Bas M; Friebe-Hoffmann U; Klussmann JP; Scheckenbach K; Balz V; Bier H; Whiteside TL
    Int J Cancer; 2006 Apr; 118(8):1984-91. PubMed ID: 16284959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
    Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
    J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.
    Peng S; Wang JW; Karanam B; Wang C; Huh WK; Alvarez RD; Pai SI; Hung CF; Wu TC; Roden RB
    PLoS One; 2015; 10(1):e116389. PubMed ID: 25560237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11.
    Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y
    Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.
    Zhang X; Luo M; Dastagir SR; Nixon M; Khamhoung A; Schmidt A; Lee A; Subbiah N; McLaughlin DC; Moore CL; Gribble M; Bayhi N; Amin V; Pepi R; Pawar S; Lyford TJ; Soman V; Mellen J; Carpenter CL; Turka LA; Wickham TJ; Chen TF
    Nat Commun; 2021 May; 12(1):2637. PubMed ID: 33976146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
    Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
    Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.